[Challenges in optimizing targeted complement inhibitor therapy for paroxysmal nocturnal hemoglobinuria in an expanding treatment landscape].

The advent of the C5 inhibitor eculizumab marked a paradigm shift in the management of PNH, transforming it from "a rare disease with a poor prognosis" to "a manageable disease". However, emerging challenges such as primary nonresponse due to C5 gene…

Preview only. Read the full abstract at the source